Imaging of Epidermal Growth Factor Receptor Expression in Head and Neck Cancer with SPECT/CT and 111In-Labeled Cetuximab-F(ab′)2

@article{vanDijk2013ImagingOE,
  title={Imaging of Epidermal Growth Factor Receptor Expression in Head and Neck Cancer with SPECT/CT and 111In-Labeled Cetuximab-F(ab′)2},
  author={Laura K van Dijk and Bianca A.W. Hoeben and Johannes H.A.M. Kaanders and Gerben M. Franssen and Otto C Boerman and Johan Bussink},
  journal={The Journal of Nuclear Medicine},
  year={2013},
  volume={54},
  pages={2118 - 2124}
}
Combined treatment of advanced head and neck squamous cell carcinomas (HNSCC) with radiotherapy and the epidermal growth factor receptor (EGFR) inhibitor cetuximab improves clinical outcome in comparison to radiotherapy alone but is effective only in a few cases. To select those patients most likely to benefit from EGFR inhibition, it can be advantageous to quantify the tumor EGFR status before and possibly during therapy. The aim of this study was to develop and characterize the 111In… 

Figures and Tables from this paper

PET of EGFR with (64) Cu-cetuximab-F(ab')2 in mice with head and neck squamous cell carcinoma xenografts.

TLDR
Clinically, this tracer has the potential to be used to determine cetuximab targeting of tumors and possibly to non-invasively monitor the response to EGFR-inhibitor treatment and is a promising PET tracer to determine expression of EGFR in vivo.

111In-Cetuximab-F(ab′)2 SPECT and 18F-FDG PET for Prediction and Response Monitoring of Combined-Modality Treatment of Human Head and Neck Carcinomas in a Mouse Model

TLDR
111In-cetuximab-F(ab′)2 predicted and monitored the effects of EGFR inhibition or irradiation during treatment in both head and neck carcinoma models investigated, whereas 18F-FDG PET only correlated with tumor response in the SCCNij202 model.

Affibody-Based PET Imaging to Guide EGFR-Targeted Cancer Therapy in Head and Neck Squamous Cell Cancer Models

TLDR
In vivo studies demonstrated that coinjecting 10 μg of nonlabeled molecules with 89Zr-deferoxamine-ZEGFR:03115 allows for clear tumor visualization 3 h after injection, and a strong correlation was observed between PET analysis, ex vivo estimates of tracer concentration, and receptor expression in tumor tissues.

Early Response Monitoring with 18F-FDG PET and Cetuximab-F(ab′)2-SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model

TLDR
EGFR accessibility can be visualized with 111In-cetuximab-F(ab′)2 SPECT before and after radiotherapy, implying that the tracer can be used to measure irradiation-induced changes of EGFR expression and can monitor the compensatory response of tumors to radiotherapy.

89Zr-DFO-Cetuximab as a Molecular Imaging Agent to Identify Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma.

TLDR
It is shown that 89Zr-DFO-cetuximab is suitable for identification of EGFR downregulation in vitro and in vivo and may be useful for monitoring resistance in HNSCC patients during cetUXimab therapy.

89 Zr-DFO-Cetuximab as a Molecular Imaging Agent to Identify Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma

TLDR
It is shown that 89 Zr-DFO-cetuximab is suitable for identification of EGFR downregulation in vitro and in vivo and may be useful for monitoring resistance in HNSCC patients during cetUXimab therapy.

Zr-DFO-Cetuximab as a Molecular Imaging Agent to Identify Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma

TLDR
The authors showed that Zr-DFO-cetuximab is suitable for identification of EGFR downregulation in vitro and in vivo and may be useful for monitoring resistance in HNSCC patients during cetUXimab therapy.

Epidermal growth factor receptor imaging in human head and neck cancer xenografts

TLDR
Preclinical studies have shown that radioresistant tumors had a higher tracer uptake after irradiation, probably due to upregulation of membranous EGFR, thereby increasing target availability possibly as a compensation mechanism.

111In-cetuximab as a diagnostic agent by accessible epidermal growth factor (EGF) receptor targeting in human metastatic colorectal carcinoma

TLDR
It is suggested that 111In-cetuximab will be a potential tool for detecting EGF receptor expression in human metastatic colorectal carcinoma.

Noninvasive Evaluation of EGFR Expression of Digestive Tumors Using 99mTc-MAG3-Cet-F(ab′)2-Based SPECT/CT Imaging

TLDR
SPECT/CT imaging using 99mTc-MAG3-Cet-F(ab′)2 enables the evaluation of the EGFR expression in murine EGFR-positive tumors, indicating the potential utility for noninvasive evaluation ofThe EGFRexpression in tumors.

References

SHOWING 1-10 OF 35 REFERENCES

Radiolabeled cetuximab: Dose optimization for epidermal growth factor receptor imaging in a head‐and‐neck squamous cell carcinoma model

TLDR
This study suggests that, at optimal cetuximab imaging dose, 111In‐cetUXimab can be used for visualization of EGFR expression in head‐and‐neck squamous cell carcinoma using SPECT.

Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors.

TLDR
64Cu-DOTA-cetuximab is a potential agent for imaging EGFR-positive tumors in humans and was relatively stable in the blood of tumor-bearing mice; however, there was significant metabolism in the liver and tumors.

Disparity Between In Vivo EGFR Expression and 89Zr-Labeled Cetuximab Uptake Assessed with PET

TLDR
The results indicate a disparity between antibody uptake and expression levels of a biologic target in a tumor, suggesting that additional pharmacokinetic or pharmacodynamic mechanisms influence tumor delivery of this therapy.

Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody

TLDR
The success of EGFR-positive tumor imaging using 64Cu-DOTA-cetuximab can be translated into the clinic to characterize the pharmacokinetics, to select the right population of patients for EGFR -targeted therapy, and to monitor the therapeutic efficacy of anti-EGFR treatment.

Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting

TLDR
EGFRvIII is expressed in HNSCC where it contributes to enhanced growth and resistance to targeting wild-type EGFR, and the antitumor efficacy of EGFR targeting strategies may be enhanced by the addition of EG FRvIII-specific blockade.

Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma.

TLDR
It is concluded that treatment with an MAb that inhibits EGF receptor function is safe at the doses and schedule studied and further studies are warranted to explore the potential therapeutic efficacy of anti-EGF receptor MAbs.

PET of Hypoxia with 89Zr-Labeled cG250-F(ab′)2 in Head and Neck Tumors

TLDR
Investigation of whether 89Zr-labeled cG250-F(ab′)2 allowed visualization of tumor hypoxia using small-animal PET and whether the tracer showed spatial correlation to the microscopic distribution of CAIX-expressing cells in a human head and neck xenograft tumor model showed rapid accumulation.

Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.

TLDR
This correlative study in a large series of patients revealed that EGFR expression, which varied considerably among HNSCCs, was a strong independent prognostic indicator for OS and DFS and a robust predictor for LR relapse but not for distant metastasis.

Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII.

  • H. AertsL. Dubois P. Lambin
  • Biology, Medicine
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • 2007

Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status

TLDR
The quantitative measure of [11C]erlotinib uptake, that is, volume of distribution (VT), was significantly higher in NSCLCs tumors with EGFR exon 19 deletions, than in those without activating mutations.